Literature DB >> 15993453

The human genome project and novel aspects of cytochrome P450 research.

Magnus Ingelman-Sundberg1.   

Abstract

Currently, 57 active cytochrome P450 (CYP) genes and 58 pseudogenes are known to be present in the human genome. Among the genes discovered by initiatives in the human genome project are CYP2R1, CYP2W1, CYP2S1, CYP2U1 and CYP3A43, the latter apparently encoding a pseudoenzyme. The function, polymorphism and regulation of these genes are still to be discovered to a great extent. The polymorphism of drug metabolizing CYPs is extensive and influences the outcome of drug therapy causing lack of response or adverse drug reactions. The basis for the differences in the global distribution of the polymorphic variants is inactivating gene mutations and subsequent genetic drift. However, polymorphic alleles carrying multiple active gene copies also exist and are suggested in case of CYP2D6 to be caused by positive selection due to development of alkaloid resistance in North East Africa about 10,000-5000 BC. The knowledge about the CYP genes and their polymorphisms is of fundamental importance for effective drug therapy and for drug development as well as for understanding metabolic activation of carcinogens and other xenobiotics. Here, a short review of the current knowledge is given.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993453     DOI: 10.1016/j.taap.2005.01.030

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  19 in total

Review 1.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

2.  CYP2D6 polymorphisms in patients with porphyrias.

Authors:  Jimena V Lavandera; Victoria E Parera; Alcira Batlle; Ana María Buzaleh
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

3.  Drug-gene interactions: inherent variability in drug maintenance dose requirements.

Authors:  Paul Westervelt; Kihoon Cho; David R Bright; David F Kisor
Journal:  P T       Date:  2014-09

4.  A translational bioinformatic approach in identifying and validating an interaction between Vitamin A and CYP19A1.

Authors:  Santosh Philips; Jing Zhou; Zhigao Li; Todd C Skaar; Lang Li
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

Review 5.  Clinically relevant genetic variations in drug metabolizing enzymes.

Authors:  Navin Pinto; M Eileen Dolan
Journal:  Curr Drug Metab       Date:  2011-06       Impact factor: 3.731

Review 6.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

Review 7.  Predicting the clinical relevance of drug interactions from pre-approval studies.

Authors:  Silvio Caccia; Silvio Garattini; Luca Pasina; Alessandro Nobili
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.

Authors:  Sarah C Preissner; Michael F Hoffmann; Robert Preissner; Mathias Dunkel; Andreas Gewiess; Saskia Preissner
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

9.  A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.

Authors:  Eva Maria Hodel; Serej D Ley; Weihong Qi; Frédéric Ariey; Blaise Genton; Hans-Peter Beck
Journal:  Malar J       Date:  2009-12-09       Impact factor: 2.979

10.  SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions.

Authors:  Saskia Preissner; Katharina Kroll; Mathias Dunkel; Christian Senger; Gady Goldsobel; Daniel Kuzman; Stefan Guenther; Rainer Winnenburg; Michael Schroeder; Robert Preissner
Journal:  Nucleic Acids Res       Date:  2009-11-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.